2024
Prescription Drug Prices: An AAN Position Statement.
Santoro J, Sico J, Burke J, Sarkar K, Turbes M, Evans D, Jordan J. Prescription Drug Prices: An AAN Position Statement. Neurology 2024, 102: e209132. PMID: 38335469, DOI: 10.1212/wnl.0000000000209132.Peer-Reviewed Original ResearchMeSH KeywordsBiosimilar PharmaceuticalsHumansNervous System DiseasesOrphan Drug ProductionPrescription DrugsPrescriptionsUnited StatesConceptsHigh cost of medicationNeurological disordersDevelopment of novel therapeuticsNeurological diseasesOrphan Drug ActTherapeutic optionsCost of medicationsHigh-value careCost of prescription drugsPrescription drug pricesRare diseaseTreat rare diseasesPatientsNovel therapeuticsTreat neurological disordersDrug ActCost containment effortsChronic neurological conditionsEffective prescription medicationsMedicationPrescriber accessPrescription medicationsTherapyHealthcare systemApproval pathway
2020
Association of prescription opioids and incident cardiovascular risk factors among post-9/11 Veterans
Chui PW, Gordon KS, Dziura J, Burg MM, Brandt CA, Sico JJ, Leapman MS, Cavanagh CE, Rosman L, Haskell S, Becker WC, Bastian LA. Association of prescription opioids and incident cardiovascular risk factors among post-9/11 Veterans. Preventive Medicine 2020, 134: 106036. PMID: 32097753, DOI: 10.1016/j.ypmed.2020.106036.Peer-Reviewed Original ResearchConceptsCVD risk factorsLong-term opioid therapyCurrent smoking statusRisk factorsOpioid useOpioid therapySmoking statusCardiovascular diseaseHigh riskLong-term exposureIncident cardiovascular risk factorsModifiable CVD risk factorsPrevalent CVD risk factorsFirst primary care visitCardiovascular risk factorsPrimary care visitsBaseline periodElectronic health record dataMain outcome measuresHealth record dataOpioid prescriptionsCare visitsPrescription opioidsMain exposureOutcome measures